Fas and FasL Gene Expression in Gynaecological Cancers
Author Information
Author(s): Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R
Primary Institution: Hyogo Institute of Clinical Research
Hypothesis
The study evaluates the expression of Fas and FasL genes in various gynaecological carcinomas.
Conclusion
Down-regulation of Fas expression is a common abnormality in many types of gynaecological cancers.
Supporting Evidence
- Down-regulation of Fas expression is more prominent than the up-regulation of FasL expression in all types of gynaecological cancer studied.
- Only one cervical carcinoma cell line exhibited a high level of FasL expression.
Takeaway
The study found that in many gynaecological cancers, the Fas gene is less active, which may help cancer cells avoid the immune system.
Methodology
Real-time quantitative reverse transcription polymerase chain reaction analysis was used to evaluate gene expression.
Participant Demographics
The study included 31 ovarian, 29 cervical, and 25 endometrial carcinoma tissues, along with ovarian and cervical carcinoma cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website